Alternative splicing is an important part of the regular process of gene expression. It controls time and tissue dependent expression of specific splice forms and depends on the correct function of about 100 splicing factor proteins of which many are the product of alternative splicing itself. It is therefore not surprising that even minor sequence disturbances can cause mis-spliced gene products with pathological effects. We survey some common diseases which can be traced back to a malfunction of alternative splicing including cystic fibrosis, beta-thalassemia, spinal muscular atrophy and cancer. Often cancer also results from even mis-spliced splicing factors leading to randomly spliced non-functional isoforms of several genes.
The hypotheses of Beadle and Tatum (1941), that one gene codes for a single uniquely defined protein, has been disproved many times during the past 30 years by discovering a number of ways how one single gene gives rise to different gene products. The differences may result at the transcriptional level, during RNA pre-processing, m-RNA translation or post-translational protein processing and folding. A recent review by Boeckmann et al. (2005) describes the most important ways of gene product modification.
Alternative splicing increases the diversity of gene products by deriving different final mRNAs from the same pre-mRNA transcript by alternative definition of introns which are spliced out to derive the final mRNA used for translation. But whereas the process of splicing, the interaction of different proteins forming the spliceosome and removing an intron, is investigated and described in great detail by Staley and Guthrie (1998), Will and Luhrmann (2001), Nilsen (2003) and Tazi et al. (2005), the process of how the splice sites are selected is not yet fully understood.
For each single splicing reaction the spliceosome is newly formed in interaction with the pre-mRNA and acts in two basic steps as seen in Figure 1. Cleavage of the donor site and ligation of the 5’ end of the intron to the branch side (step 1) is followed by removal of the intron by cleavage of the acceptor site, the 3’ end of the intron, and the ligation of the neighboring exons (step 2). About hundred interacting molecular splicing factors, many of them are snRNPs, are known to steer this complex process. Four important signals on the pre-mRNA intron are essential to attract these splicing factors to form the spliceosome and to perform splicing. Theses are the donor site at the 5’ end of the intron, the branch point with the nucleotide A located about 17-40 nucleotides upstream of the acceptor site, the polypyrimidine region, and the acceptor site itself which defines the 3’ end of the intron. Exonic and intronic splicing enhancer or silencer sequence motifs additionally affect attraction of all splicing factors. If hit by mutations, all changed sequence signals are prone to change the pattern of splicing and to seriously affect protein expression, eventually causing death and disease.
The two major steps of splicing; cleavage at the donor site (5’ splice site) and forming the lariat structure (step 1) followed by removing the intron and ligating the exons (step 2)
Krawczak et al. (1992) reported about 15% of all known diseases causing point mutations to directly hit splice sites. This early publication did not consider mutations of exonic or intronic splicing enhancer or silencer signals known to be very important today. The Human Gene Mutation Database published by Stenson et al. 2003 contains 61106 registered mutations of which 5822 affect splicing events. From this set 3633 are point mutations of the GT donor and the AG acceptor splice sites. Skipped exons induced by these mutations often change the reading frame and create aberrant not functional proteins. Mutations within exons, which do not change the resulting proteins, are considered neutral or silent. Still they can damage splicing enhancer or silencer motifs. Studies of the NF1 (Neurofibromatosis type 1) and ATM (Ataxia telangiectasia) mutated gene by Teraoka et al. (1999) and Ars et al. (2000) found that even 50% of the disease causing mutations imply splicing mistakes. Characterization of these splicing defects can help to understand diseases and to find novel strategies for diagnostics and therapy.
Even the normal process of alternative splicing is very complex. Reports by Mironov et al. (1999), Johnson et al. (2003) and Gupta et al. (2004) reported alternative RNA splicing for 35% to 75% of the human genes. Although these numbers must be handled with care, they surely imply that mutations can easily harm the natural balance of alternative splice products and lead to diseases and cancer.
Key Terms in this Chapter
Exon: An exon is a part of the pre-mRNA that is not removed during the RNA-splicing process.
Hereditary Disease: A genetic disorder is called a hereditary disease.
Spliceosome: The entire assembly of proteins that facilitates pre-mRNA splicing.
Intronic Splicing Enhancer/Silences: A pre-mRNA sequence motif of about six bases within an intron regulating enhanced/silenced splicing at a close by sequence position.
Human Gene Mutation Database: The Human Gene Mutation Database (HGMD) constitutes a comprehensive core collection of data on germ-line mutations in nuclear genes underlying or associated with human inherited disease ( www.hgmd.org ).
Autosomal Recessive Disorder: Disorder that only occurs if both alleles of a pair of autosomal chromosomes are mutated.
Ligation: The joining of two molecules facilitated by an enzyme called ligase. In our context ligation denotes the joining of exon fragments during pre-mRNA splicing.
CFTR (Cystic Fibrosis Transmembrane conductance Regulator): CFTR is an ion channel protein belonging to the class of ABC transporters. It transports chloride ions through the cell membrane. Dysfunction of this protein causes the Cystic fibrosis.
Intron: A pre-mRNA fragment that is cleaved out during pre-mRNA splicing.
Alternative Splicing: Alternative choice of introns which are spliced out during pre-mRNA processing.
Exonic Splicing Enhancer/Silencer: A pre-mRNA sequence motif of about six bases within an exon regulating enhanced/silenced splicing at a close by sequence position.
Beta-Globin Gene: Gene that codes for the beta globin chain of the hemoglobin protein.
Hyperexcitability: A mutation in a cation ion channel which leads persistent muscle contractions caused by increased cell membrane voltage.
Thalassemia: Severe heriditary disease caused by mutations in the beta-globin gene sequence.
Complete Chapter List
Peter Wellstead, Sree Sreenath, Kwang-Hyun Cho
Nikolaos G. Sgourakis, Pantelis G. Bagos, Stavros J. Hamodrakas
Pantelis G. Bagos, Stavros J. Hamodrakas
George Sakellaropoulos, Antonis Daskalakis, George Nikiforidis, Christos Argyropoulos
Djork-Arné Clevert, Axel Rasche
R. Seigneuric, N.A.W. van Riel, M.H.W. Starmans, A. van Erk
Matej Orešic, Antonio Vidal-Puig
Alia Benkahla, Lamia Guizani-Tabbane, Ines Abdeljaoued-Tej, Slimane Ben Miled, Koussay Dellagi
Daniela Albrecht, Reinhard Guthke
Ferda Mavituna, Raul Munoz-Hernandez, Ana Katerine de Carvalho Lima Lobato
Roberta Alfieri, Luciano Milanesi
Michael R. Hamblin
Alexey R. Brazhe, Nadezda A. Brazhe, Alexey N. Pavlov, Georgy V. Maksimov
Cathrin Dressler, Olaf Minet, Urszula Zabarylo, Jürgen Beuthan
Athina Theodosiou, Charalampos Moschopoulos, Marc Baumann, Sophia Kossida
Bernard de Bono
Isabel Reinecke, Peter Deuflhard